What question did this study set out to answer?

February 21, 2026BMC CancerOpen Access

Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients

View Full Paper

Ask AI

Bookmark

Authors

YLYufang LuAnhui Medical University PLPengcheng LiuAnhui Medical University CMChunyan MaAnhui Medical University

Discussion

Member takes

Implication

A retrospective cohort analyzed the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer, suggesting improved outcomes with combination therapy.

Key Points

This study aims to evaluate the real-world efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer compared to chemotherapy alone.
Retrospective cohort study of 208 patients with advanced NSCLC.
Patients divided into two groups: 104 received chemotherapy alone, 104 received chemo-immunotherapy.
Analyzed progression-free survival (PFS) and overall survival (OS) using Kaplan–Meier and Cox proportional hazards models.
Subgroup analyses performed based on metastatic sites, smoking status, and adverse events.
Combination therapy significantly improved median PFS (9.7 vs. 3.7 months; P < 0.001) and OS (17.8 vs. 10.3 months; P < 0.001).
3-year OS rate was higher in the combination group (31.7% vs. 12.2%).
Poor ECOG status, lymph node metastases, and single-agent chemotherapy linked to shorter PFS in the chemotherapy group.
In the combination group, smoking, liver metastases, and severe adverse events predicted worse PFS.

Cite This Study

Lu et al. (2026) studied this question.

synapsesocial.com/papers/69994bef873532290d01ffcc https://doi.org/10.1186/s12885-026-15738-4

View Full Paper

Ask AI

Bookmark

Implication

A retrospective cohort analyzed the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer, suggesting improved outcomes with combination therapy.

Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider